CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Metformin Glycinate +1 moredrug
Likely dose
Metformin Glycinate 620 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04625985
NCT04625985Phase 2Completed
CompareCT.gov

Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb

Laboratorios Silanes S.A. de C.V.·interventional·Posted Nov 12, 2020·Updated Apr 8, 2021

In Brief

A Phase 2 clinical trial evaluating Metformin Glycinate and Placebo oral tablet for Severe Acute Respiratory Syndrome Coronavirus 2. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Acute Respiratory Syndrome Coronavirus 2
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 12, 2020
Enrollment StartJul 14, 2020
Primary CompletionMar 8, 2021
Study CompletionMar 18, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.6 years ago

Interventions

Metformin Glycinatedrug

Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment

Placebo oral tabletdrug

Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment